Category - Markets

Markets

BTIG cuts electroCore to neutral

BTIG downgraded electroCore (NASDAQ:ECOR) to a “neutral” rating following the company’s release of its first quarter 2019 results. The stock closed at $5.33 on May 14.

May 15, 2019

Markets

BTIG ups TransEnterix to buy; PT $3

BTIG upgraded TransEnterix (NASDAQ:TRXC) to “buy” from “neutral” with a price target of $3, saying it sees more upside potential than downside risk at current share prices.

May 14, 2019

Markets

Roth starts Seelos Therapeutics at buy; PT $8

Roth Capital partners launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $8 price target. The stock closed at $2.71 on May 13.

May 14, 2019

Markets

BTIG starts MannKind at buy; PT $3

BTIG initiated coverage of MannKind (NASDAQ:MNKD) with a “buy” rating and price target of $3. The stock closed at $1.23 on May 13.

May 14, 2019

Markets

Alliance Global starts Canopy Growth at buy; PT $75 (Canadian)

Alliance Global Partners launched coverage of Canopy Growth (TSX:WEED; NYSE:CGC) with a “buy” rating and $75 price target. The stock closed at $63.78 on May 10.

May 13, 2019

Markets

SVB Leerink starts Turning Point Therapeutics at OP; PT $42

SVB Leerink launched coverage of Turning Point Therapeutics (NASDAQ:TPTX) with an “outperform” rating and $42 price target. The stock closed at $32.12 on May 10.

May 13, 2019

Markets

SVB Leerink starts Hookipa Pharma at OP; PT $20

SVB Leerink initiated coverage of Hookipa Pharma (NASDAQ:HOOK) with an “outperform” rating and $20 price target. The stock closed at $13.85 on May 10.

May 13, 2019

Markets

Canaccord ups ShockWave Medical PT to $50 from $39

Canaccord Genuity raised its price target for ShockWave Medical (NASDAQ:SWAV) to $50 from $39 after the company’s first quarter results beat consensus estimates.

May 9, 2019

Markets

Stifel ups Protagonist Therapeutics to buy; PT up to $17 from $11

Stifel upgraded Protagonist Therapeutics (NASDAQ:PTGX) to “buy” from “neutral” and raised its price target to $17 from $11 after expansion of a deal with Janssen for PTG-200 and other IL-23 receptor antagonists. The...

May 9, 2019

Markets

Canaccord cuts OraSure to hold; PT down to $10 from $16

Canaccord Genuity downgraded OraSure Technologies (NASDAQ:OSUR) to “hold” from “buy” and dropped its price target to $10 from $16, citing disappointment of underlying trends in direct-to-consumer (DTC) genetic testing...

May 9, 2019

Category - Markets

Subscribe